Progyny (PGNY) Stock Forecast & Price Target

$14.97 +0.99 (+7.08%)

(As of 11/21/2024 ET)

Progyny - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 13 Analyst Ratings

Sell
0

Hold
8

Buy
5

Based on 13 Wall Street analysts who have issued ratings for Progyny in the last 12 months, the stock has a consensus rating of "Hold." Out of the 13 analysts, 8 have given a hold rating, and 5 have given a buy rating for PGNY.

Consensus Price Target

$25.42
69.78% Upside

According to the 13 analysts' twelve-month price targets for Progyny, the average price target is $25.42. The highest price target for PGNY is $43.00, while the lowest price target for PGNY is $17.00. The average price target represents a forecasted upside of 69.78% from the current price of $14.97.

Get the Latest News and Ratings for PGNY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Progyny and its competitors.

PGNY Analyst Ratings Over Time

Type	Current Forecast 11/23/23 to 11/22/24	1 Month Ago 10/24/23 to 10/23/24	3 Months Ago 8/25/23 to 8/24/24	1 Year Ago 11/23/22 to 11/23/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	5 Buy rating(s)	5 Buy rating(s)	7 Buy rating(s)
Hold	8 Hold rating(s)	7 Hold rating(s)	6 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$25.42	$27.73	$31.90	$47.00
Forecasted Upside	69.78% Upside	74.83% Upside	46.33% Upside	39.18% Upside
Consensus Rating	Hold	Hold	Hold	Moderate Buy

Can Trump Make Housing Great Again? (Ad)

Trump won. But can he undo the damage the Democrats have inflicted on this nation? Under Biden, inflation soared 20%... Which could be the final blow for the American Dream - even with Trump in office.

Take these three steps today to protect your retirement from Biden's legacy >>>

PGNY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

PGNY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Progyny Stock vs. The Competition

Type	Progyny	Medical Companies	S&P 500
Consensus Rating Score	2.38	2.80	2.50
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	69.78% Upside	26,677.72% Upside	8.51% Upside
News Sentiment Rating	Neutral News See Recent PGNY News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/14/2024	Barclays 3 of 5 stars		Lower Target	Overweight ➝ Overweight	$30.00 ➝ $17.00	+22.30%
11/13/2024	Bank of America 4 of 5 stars		Lower Target	Buy ➝ Buy	$22.00 ➝ $21.00	+49.15%
11/13/2024	Canaccord Genuity Group 1 of 5 stars		Lower Target	Hold ➝ Hold	$18.00 ➝ $17.00	-1.05%
11/13/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Singh Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$26.00 ➝ $19.00	+10.59%
10/1/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$25.00 ➝ $25.00	+53.56%
9/19/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$31.00 ➝ $24.00	+45.81%
What Comes Next Could Be a Once-in-a-Lifetime Opportunity (Ad) A wave of technological and financial transformation is reshaping the investment landscape. For those who understand the shifts ahead, this could be the foundation for long-term wealth creation. In this exclusive briefing, I'll show you exactly how to prepare for the challenges and opportunities ahead. You'll learn actionable strategies to protect your portfolio and position yourself for growth in the months and years to come. Click here now to watch the full briefing and discover the steps to take today.
9/19/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$31.00 ➝ $22.00	+28.28%
9/19/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Market Perform ➝ Market Perform	$25.00 ➝ $21.00	-14.08%
9/19/2024	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Davides Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
8/7/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Cherny Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/7/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Larsen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
5/10/2024	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Schoenhaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Sector Weight

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 01:53 AM ET.

PGNY Forecast - Frequently Asked Questions

: According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Progyny is $25.42, with a high forecast of $43.00 and a low forecast of $17.00.
: 13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Progyny in the last year. There are currently 8 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PGNY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PGNY, but not buy additional shares or sell existing shares.
: According to analysts, Progyny's stock has a predicted upside of 69.78% based on their 12-month stock forecasts.
: Over the previous 90 days, Progyny's stock had 1 downgrade by analysts.
: Progyny has been rated by research analysts at Bank of America, Barclays, Canaccord Genuity Group, Cantor Fitzgerald, Jefferies Financial Group, JMP Securities, JPMorgan Chase & Co., Leerink Partners, and Truist Financial in the past 90 days.
: Analysts like Progyny less than other "medical" companies. The consensus rating for Progyny is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how PGNY compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

What Comes Next Could Be a Once-in-a-Lifetime Opportunity (Ad)

A wave of technological and financial transformation is reshaping the investment landscape. For those who understand the shifts ahead, this could be the foundation for long-term wealth creation. In this exclusive briefing, I'll show you exactly how to prepare for the challenges and opportunities ahead. You'll learn actionable strategies to protect your portfolio and position yourself for growth in the months and years to come.

Click here now to watch the full briefing and discover the steps to take today.

This page (NASDAQ:PGNY) was last updated on 11/22/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Progyny (PGNY) Stock Forecast & Price Target